Advertisement

Clinical Presentation

  • Frank Berthold
  • Thorsten Simon
Part of the Pediatric Oncology book series (PEDIATRICO)

Keywords

Clin Oncol Olfactory Neuroblastoma Neuroblastoma Patient MYCN Gene Neuroblastic Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel F et al. (1999) Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 81:1402–1409CrossRefPubMedGoogle Scholar
  2. Ambros I et al. (1996) Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 334:1505–1511CrossRefPubMedGoogle Scholar
  3. Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504CrossRefPubMedGoogle Scholar
  4. Berthold F, Harms D, Lampert F, Niethammer D, Zieschang J (1990) Risk factors in neuroblastoma of infants. Contrib Oncol 41:101–117Google Scholar
  5. Berthold F et al. (1992a) Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 14:207–215PubMedGoogle Scholar
  6. Berthold F et al. (1992b) Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Eur J Cancer 28A:1950–1954CrossRefPubMedGoogle Scholar
  7. Berthold F et al. (1994) Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 16:107–115PubMedGoogle Scholar
  8. Berthold F et al. (1998) Are spontaenous regressions of neuroblastoma delayed embryofetal involutions? Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen? In: Hein E, Schwarz, Stuttgard R (eds) Spontanremissionen in der Onkologie: theoretische Modelle und klinische Befunde. Schattauer, New York, pp 84–94Google Scholar
  9. Bown N et al. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954–1961PubMedGoogle Scholar
  10. Brodeur GM et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477PubMedGoogle Scholar
  11. Brodeur GM et al. (1997) Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93–101CrossRefPubMedGoogle Scholar
  12. Castleberry RP et al. (1994) The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 12:2378–2381PubMedGoogle Scholar
  13. Cohn SL et al. (1995) Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res 55:721–726PubMedGoogle Scholar
  14. Combaret V et al. (1996) Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14:25–34PubMedGoogle Scholar
  15. Combaret V et al. (1997) Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Br J Cancer 75:1151–1155PubMedGoogle Scholar
  16. Combaret V et al. (2002) Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res 62:3646–3648PubMedGoogle Scholar
  17. Cooper R et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features — a report from the Children's Cancer Group. Med Pediatr Oncol 36:623–629CrossRefPubMedGoogle Scholar
  18. Cotterill SJ et al. (2000) Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982–1992. Eur J Cancer 36:901–908CrossRefPubMedGoogle Scholar
  19. Cushing HSW (1927) The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol 3:203–216Google Scholar
  20. De Bernardi B et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19:183–190PubMedGoogle Scholar
  21. De la Monte SM et al. (1983) Nonrandom distribution of metastases in neuroblastic tumors. Cancer 52:915–925PubMedGoogle Scholar
  22. Dluhy RG (2002) Pheochromocytoma: death of an axiom. N Engl J Med 346:1486–1488CrossRefPubMedGoogle Scholar
  23. DuBois SG et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189CrossRefPubMedGoogle Scholar
  24. Dulguerov P et al. (2001) Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2:683–690CrossRefPubMedGoogle Scholar
  25. El Shafie M et al. (1983) Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 18:34–36PubMedGoogle Scholar
  26. Evans AE et al. (1971) A proposed staging for children with neuroblastoma. Cancer 27:374–378PubMedGoogle Scholar
  27. Evans AE et al. (1990) A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group. J Clin Oncol 8:678–588PubMedGoogle Scholar
  28. Garaventa A et al. (2002) Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 13:956–964CrossRefPubMedGoogle Scholar
  29. Geoerger B et al. (2001) Metabolic activity and clinical features of primary ganglioneuromas. Cancer 91:1905–1913CrossRefPubMedGoogle Scholar
  30. Greenberg RE (1957) New diagnostic test for neural tumors in infancy: increased urinary excretion of 3-methoxy-4-hydroxymandelic acid and norepinephrin in a ganglioneuroma with chronic diarrhea. Pediatrics 24:683–684Google Scholar
  31. Guo C et al. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18:4948–4957PubMedGoogle Scholar
  32. Hallstensson K et al. (1997) Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur J Cancer 33:1966–1970CrossRefPubMedGoogle Scholar
  33. Hann HW, Bombardieri E (2000) Serum markers and prognosis in neuroblastoma: Ferritin, LDH, NSE. In: Brodeur G, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 371–381Google Scholar
  34. Hann HW et al. (1981) Biologic differences between neuroblastoma stages IV–S and IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med 305:425–429PubMedGoogle Scholar
  35. Hann HW et al. (1985) Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 45:2843–2848PubMedGoogle Scholar
  36. Hero B et al. (2001) Evaluation of catecholamine metabolites, MIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol 36:220–223CrossRefPubMedGoogle Scholar
  37. Hero B et al. (2002) Neuroblastoma preoperatively treated as nephroblastoma: Does inadequate therapy worsen the prognosis? Klin Padiatr 214:157–161CrossRefPubMedGoogle Scholar
  38. Hero B et al. (2000) Regression in stage 2 and 3 infant neuroblastoma: results of the prospective German neuroblastoma trial. Adv Neuroblastoma Res. Abstract,15–18 May, Philadelphia, P20Google Scholar
  39. Hsiao RJ et al. (1990) Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555–1559PubMedGoogle Scholar
  40. Hutchinson R (1907) On suprarenal sarcoma in children with metastases in the skull. Q J Med 1:33–38Google Scholar
  41. Ikeda H et al. (2002) Experience with international neuroblastoma staging system and pathology classification. Br J Cancer 86:1110–1116CrossRefPubMedGoogle Scholar
  42. Jaffe R et al. (1984) The neuroectodermal tumor of bone. Am J Surg Pathol 8:885–898PubMedGoogle Scholar
  43. Kaneko M et al. (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613–621CrossRefPubMedGoogle Scholar
  44. Katzenstein HM et al. (2001) Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 19:1047–1055PubMedGoogle Scholar
  45. Khan J et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673–679CrossRefPubMedGoogle Scholar
  46. Kogner et al. (1993) Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol 21:317–322PubMedGoogle Scholar
  47. Kramer K et al. (1997) Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma. Eur J Cancer 33:2090–2091PubMedGoogle Scholar
  48. Krams M et al. (2002) Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 94:854–861CrossRefPubMedGoogle Scholar
  49. Kushner BH et al. (1996) International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 14:2174–2180PubMedGoogle Scholar
  50. Ladenstein R et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953–965PubMedGoogle Scholar
  51. Ladenstein R et al. (2001) Prognostic significance of DNA ditetraploidy in neuroblastoma. Med Pediatr Oncol 36:83–92CrossRefPubMedGoogle Scholar
  52. Lastowska M et al. (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080–3090PubMedGoogle Scholar
  53. Lau L (2002) Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 19:79–89CrossRefPubMedGoogle Scholar
  54. Laug WE et al. (1978) Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62:77–83PubMedGoogle Scholar
  55. Lilling G et al. (1994) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 5:231–239PubMedGoogle Scholar
  56. Look AT et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581–591PubMedGoogle Scholar
  57. Marchand F (1891) Beiträge zur Kenntnis der normalen und pathologischen Anatomie der Glandula carotica und der Nebennieren. Virchows Arch 5:578Google Scholar
  58. Maris JM et al. (2001) Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 36:32–36CrossRefPubMedGoogle Scholar
  59. Mason GA, Hart-Mercer J, Miller E (1957) Adrenalin-secreting neuroblastoma in an infant. Lancet 273:322–325CrossRefPubMedGoogle Scholar
  60. Mathew P et al. (2001) Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3:105–109CrossRefPubMedGoogle Scholar
  61. Mora J et al. (2001) Neuroblastic and schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 61:6892–6898PubMedGoogle Scholar
  62. Ng YY, Kingston JE (1993) The role of radiology in the staging of neuroblastoma. Clin Radiol 47:226–235PubMedGoogle Scholar
  63. Nickerson HJ et al. (2000) Favorable biology and outcome of stage IV–S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18:477–486PubMedGoogle Scholar
  64. Norris MD et al. (1996) Expression of the gene for multidrugresistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238CrossRefPubMedGoogle Scholar
  65. Pearson ADJ, Philipp T (2000) Prognosis of low-risk and high-risk neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 551–560Google Scholar
  66. Pepper W (1901) A study of congenital sarcoma of the liver and suprarenal with the report of a case. Am J Med Sci 121:287–299Google Scholar
  67. Plantaz D et al. (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680–686CrossRefPubMedGoogle Scholar
  68. Powell JE et al. (1998) Neuroblastoma in Europe: differences in the pattern of disease in the UK. SENSE. Study group for the Evaluation of Neuroblastoma Screening in Europe. Lancet 352:682–687CrossRefPubMedGoogle Scholar
  69. Rudnick E et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies: a report from the Children's Cancer Group Study. Med Pediatr Oncol 36:612–622CrossRefPubMedGoogle Scholar
  70. Russo C et al. (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284–288CrossRefPubMedGoogle Scholar
  71. Sauvat F et al. (2002) Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 94:2474–2480CrossRefPubMedGoogle Scholar
  72. Schilling FH et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346:1047–1053CrossRefPubMedGoogle Scholar
  73. Schwab M et al. (1983) Amplified DNA with limited homology to MYCN cellular oncogene is shared by human neuroblastoma cell lines and neuroblastoma tumor. Nature 305:245–248CrossRefPubMedGoogle Scholar
  74. Seeger RC, Brodeur GM, Sather H (1985) Association of multiple copies of N-myc oncogene with rapid progression in neuroblastoma. N Engl J Med 313:1111–1116PubMedGoogle Scholar
  75. Shimada H, Roald B (2000) Histology: tumors of the neuroblastoma group. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 341–354Google Scholar
  76. Shimada H et al. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416PubMedGoogle Scholar
  77. Shimada H et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372CrossRefPubMedGoogle Scholar
  78. Shuster JJ et al. (1992) Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 15:295–303PubMedGoogle Scholar
  79. Simon T et al. (2003) Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39:1899–1903CrossRefPubMedGoogle Scholar
  80. Simon T et al. (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22:3549–3557CrossRefPubMedGoogle Scholar
  81. Spitz R et al. (2002) Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 34:299–305CrossRefPubMedGoogle Scholar
  82. Spitz R et al. (2003a) FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol 41:30–35CrossRefPubMedGoogle Scholar
  83. Spitz R et al. (2003b) Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 9:4835–4840PubMedGoogle Scholar
  84. Stickler GB et al. (1959) Ganglioneuroma associated with chronic diarrhea and increased excretion of catecholamine. Proc Staff Meet Mayo Clin 34:548–549Google Scholar
  85. Suc A et al. (1996) Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 77:805–811CrossRefPubMedGoogle Scholar
  86. Terpe HJ et al. (1994) Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Death Differ 1:123–128Google Scholar
  87. Therasse P et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  88. Vandesompele J et al. (1998) Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23:141–152CrossRefPubMedGoogle Scholar
  89. Virchow R (1864) Hyperplasie der Zirbel und der Nebenniere. Die krankhaften Geschwulste, vols 11,18. Vorlesung 7.2.1863. Hirschwald, Berlin, pp 148–150Google Scholar
  90. Von Schweinitz D, Hero B, Berthold F (2002) The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12:402–409CrossRefPubMedGoogle Scholar
  91. White PS et al. (1995) A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2–36.3. Proc Natl Acad Sci USA, 92:5520–5524PubMedGoogle Scholar
  92. Woods WG et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041–1046CrossRefPubMedGoogle Scholar
  93. Wright J (1910) Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med 12:556–561CrossRefGoogle Scholar
  94. Yamamoto K et al. (1998) Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 16:1265–1269PubMedGoogle Scholar
  95. Zeltzer PM et al. (1983) Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 2:361–363CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Frank Berthold
  • Thorsten Simon

There are no affiliations available

Personalised recommendations